Layn(SZ:002166) Zheng Quan Shi Bao Wang·2025-08-20 14:16Core Viewpoint - The company is advancing the approval and market entry of its newly developed steviol glycoside, RebM2, which has received GRAS certification in the U.S. and is nearing domestic approval in China, indicating significant potential for growth in the natural sweetener market [1][2][3]. Group 1: Product Development and Market Potential - RebM2 is a rare, high-value steviol glycoside that meets the increasing demand for low-calorie, high-sweetness solutions in the context of global sugar reduction initiatives [2]. - The product offers a sweetness level 150 to 200 times that of sucrose, with zero calories and a favorable taste profile, addressing the limitations of traditional steviol glycosides [2][3]. - The company has successfully improved the production efficiency and cost-effectiveness of RebM2 through enzyme conversion methods, enhancing its solubility and stability [3]. Group 2: Strategic Importance and Future Plans - The completion of the public consultation phase for RebM2 in China is a crucial step for the company to accelerate its market promotion and sales efforts [3]. - The company plans to focus on the deep development of RebM2, aiming to innovate applications and expand its product matrix [4]. - The synthetic biology workshop is set to commence operations in September 2024, enabling mass production of RebM2 [3].